Patent · US Active

Reduced size self-delivering RNAi compounds

US10041073B2 · kind B2 · utility

21Cited by

173References

24Claims

0Family size

Assignee

RXi Pharmaceuticals Corporation · US

Inventors

Anastasia Khvorova · Boulder, US
William Salomon · Worcester, US
Joanne Kamens · Newton, US
Dmitry Samarsky · Berlin, DE
Tod M. Woolf · Sudbury, US
James Cardia · Franklin, US

Key dates

Filing date	Mar 23, 2011
Grant date	Aug 7, 2018
Priority date	—
Expiry date	Sep 6, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/53
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.